Episode 59
Biotech Hangout
00:00
BioNTech Beats X-Lixis and BioNtech
It was quite a mixed bag. X-Lixis missed top and bottom line, due to some gross-to-net issues with kaboometics. Then seeing an island where the new drug is launching from one Patro to a root-ray beat by 8%. And overall, there was a 3% beat. So it was quite mixed when you look across the board. But all these companies pretty much surprise the market with regards to their expectations for the full year - Novavax particularly.
Transcript
Play full episode
